Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S. Bankruptcy Court for ...

Regeneron Pharmaceuticals on Monday announced it is buying 23andMe out of bankruptcy for $256 million – taking with it the company’s extensive trove of genetic samples and data. It will ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...